BRIEF-Advaxis and Sellas announce licensing agreement for development of WT1 antigen-targeting immunotherapy
* Advaxis and Sellas announce licensing agreement for development of WT1 antigen-targeting immunotherapy
Nov 30 Avnet Inc
* Avnet announces pricing of $300 million in aggregate principal amount of notes
* Avnet Inc says priced offering of $300 million aggregate principal amount of 3.750% notes due 2021 in a registered offering Source text for Eikon: Further company coverage:
* Aclaris Therapeutics Inc - submitted a new drug application to U.S. FDA for A-101 40 percent topical solution as a treatment for seborrheic keratosis
GHAZIABAD, India, Feb 27 Struggling with customers unable to pay on time and plummeting sales, Indian small-business owner Ravi Jain fears the government's crackdown on cash will have a much larger impact than predicted by top policymakers.